Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Crit Care. 2001 Oct;7(5):347-53.

Clinical impact of novel anticoagulation strategies in sepsis.

Author information

  • 1Brown University School of Medicine, and Director, Infectious Disease Division, Memorial Hospital of Rhode Island, Pawtucket 02860, Rhode Island, USA. Steven_Opal@brown.edu

Abstract

Derangements in coagulation and fibrinolysis are frequent complications of systemic infection, and septic shock is the most common recognized cause of disseminated intravascular coagulation. Anticoagulant therapy has been used as a treatment strategy for severe sepsis for several decades without compelling evidence of efficacy until the 2001 publication of the phase III trial with recombinant human activated protein C. Major phase III international trials with antithrombin and tissue factor pathway inhibitor also have been completed recently. The molecular mechanisms by which the clotting system interacts with the innate immune response have greatly facilitated the understanding of coagulation and the pathophysiology of septic shock. Anticoagulants such as recombinant human activated protein C and related agents may become the mainstay of adjuvant therapies for severe sepsis in the near future.

PMID:
11805532
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Support Center